Cue Biopharma, Inc. (CUE) — Financial statements
Income statement, balance sheet, and cash flow for Cue Biopharma, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 27↑195.7% | 9↑69.2% | 5↑341.0% | 1↓91.7% | 15 | |
| Cost of Revenue | 3 | 0.00↓100.0% | 38 | 0.00↑100.0% | -2 | |
| Gross Profit | 24↑158.3% | 9↑128.5% | -33↓2719.0% | 1↓92.6% | 17 | |
| Operating Expenses | ||||||
| R&D Expenses | 38↑4.0% | 36↓11.0% | 41↑5.8% | 39↓6.7% | 41 | |
| General & Administrative Expenses | 16↑11.4% | 15↓12.6% | 17↑3.2% | 16↓6.6% | 17 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 16↑11.4% | 15↓12.6% | 17↑3.2% | 16↓6.6% | 17 | |
| Other Expenses | -3↓3641.9% | -0.09↑99.8% | -38↓13596.8% | -0.28↓115.6% | 2 | |
| Operating Expenses | 51↓0.6% | 51↑159.9% | 20↓64.1% | 54↓9.9% | 60 | |
| Total Costs & Expenses | 54↑6.3% | 51↓11.9% | 58↑5.8% | 54↓7.1% | 59 | |
| Operating Results | ||||||
| Operating Income | -27↑36.0% | -42↑20.4% | -52↑2.0% | -53↓21.8% | -44 | |
| Depreciation & Amortization | 3↑48.1% | 2↓31.6% | 3↑90.3% | 2↑201.6% | -2 | |
| EBITDA | -23↑38.6% | -38↑18.5% | -46↑8.8% | -50↓11.1% | -45 | |
| EBIT | -27↑33.5% | -40↑19.4% | -49↑5.4% | -52↓19.8% | -44 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.45↓45.5% | 0.83↓41.7% | 1↑558.6% | 0.22↑368.4% | 0.05 | |
| Interest Income | 0.81↓50.2% | 2↓39.0% | 3↑186.7% | 0.93↑1922.4% | 0.05 | |
| Interest Expense | 0.36↓55.2% | 0.80↓36.1% | 1↑74.4% | 0.71 | 0.00 | |
| Non-Operating Income | 0.00↑100.0% | -2↑39.0% | -3↓186.7% | -0.93↓1921.9% | -0.05 | |
| Other Income / Expenses | 0.42↓49.3% | 0.83↓41.7% | 1↑558.6% | 0.22↑368.4% | 0.05 | |
| Income Before Tax | -26↑35.8% | -41↑19.8% | -51↑4.3% | -53↓21.4% | -44 | |
| Income Tax Expense | 0.50 | 0.00 | 0.00 | 0.00↓100.0% | 0.50 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -27↑34.6% | -41↑19.8% | -51↑4.3% | -53↓20.0% | -44 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -27↑34.6% | -41↑19.8% | -51↑4.3% | -53↓20.0% | -44 | |
| Bottom-Line Net Income | -27↑34.6% | -41↑19.8% | -51↑4.3% | -53↓20.0% | -44 | |
| EPS (Basic) | -8.40↑61.1% | -21.60↑35.1% | -33.30↑25.5% | -44.70↓5.7% | -42.30 | |
| EPS (Diluted) | -8.40↑61.1% | -21.60↑35.1% | -33.30↑25.5% | -44.70↓5.7% | -42.30 | |
| Weighted Average Shares | 3↑68.2% | 2↑23.1% | 2↑28.3% | 1↑13.9% | 1 | |
| Weighted Average Diluted Shares | 3↑68.2% | 2↑23.1% | 2↑28.3% | 1↑13.9% | 1 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.